Publication:
CD63 is a diagnostic marker of prostate cancer and a prognostic marker of biochemical progression following radical prostatectomy

Simple item page
dc.contributor.authorMarit Bernhardt1
dc.contributor.authorIsabella Federica Bollen
dc.contributor.authorTobias Kreft
dc.contributor.authorAnna Katrin Scherping
dc.contributor.authorXiaolin Zhou
dc.contributor.authorManuel Ritter
dc.contributor.authorJörg Ellinger
dc.contributor.authorCarsten Stephan
dc.contributor.authorGlen Kristiansen
dc.contributor.authorElisabeth Dingendorf
dc.contributor.departmentBiología Celular e Histología
dc.date.accessioned2026-02-16T15:20:36Z
dc.date.available2026-02-16T15:20:36Z
dc.date.issued2026
dc.description.abstractAims. We aimed to analyze CD63, a cell surface protein that has been associated with tumor aggressiveness in several cancers, including breast, colorectal, and lung cancer, as well as melanoma, in prostate cancer. Methods. CD63 expression was analyzed immuno histochemically in a cohort of primary prostate cancers from 281 patients. The results were correlated with clinico-pathologic parameters, including biochemical recurrence. In addition, CD63 expression in 251 of the 281 patients with prostate cancer was compared with CD63 expression in matched benign tissue samples (490 tissue samples). The analysis was performed automatically using the open-source software QuPath© and tested for statistical significance. For comparison with the diagnostic markers AMACR and GOLPH2, CD63 was analyzed in an additional cohort of 198 prostate cancers. Results. CD63 expression was found in 100% of prostate cancer cases and benign tissue spots. Increased CD63 expression was significantly associated with higher tumor stage (pT), tumor grade (ISUP), as well as shorter progression-free survival (PFS). Compared with the CD63 intensity of benign tissue, expression in tumor tissue was higher in >80% of cases. In addition, combining the expression of CD63 and AMACR, positivity reached 97.2%, making CD63 a promising diagnostic biomarker in challenging cases. Conclusions. CD63 is commonly overexpressed in prostate cancer, and higher levels are associated with earlier biochemical tumor progression; hence, CD63 is a promising diagnostic and prognostic biomarker in primary prostate cancer.
dc.formatapplication/pdf
dc.format.extent9
dc.identifier.doihttps://doi.org/10.14670/HH-18-981
dc.identifier.issn0213-3911
dc.identifier.issn1699-5848
dc.identifier.urihttp://hdl.handle.net/10201/206001
dc.languageeng
dc.relationUniversidad de Murcia, Departamento de Biologia Celular e Histiologia
dc.relationSin financiación externa a la Universidad
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectImmunohistochemistry
dc.subjectCD63
dc.subjectBiomarker
dc.subjectTetraspanin
dc.subjectProstate cancer
dc.subject.odsNo relacionado con ningún objetivo de desarrollo sostenible
dc.titleCD63 is a diagnostic marker of prostate cancer and a prognostic marker of biochemical progression following radical prostatectomy
dc.typeinfo:eu-repo/semantics/article
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dingendorf-41-421-429-2026.pdf
Size:
2.67 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology, Vol.41, Nº3, (2026)